Mascola J R, Snyder S W, Weislow O S, Belay S M, Belshe R B, Schwartz D H, Clements M L, Dolin R, Graham B S, Gorse G J, Keefer M C, McElrath M J, Walker M C, Wagner K F, McNeil J G, McCutchan F E, Burke D S
Division of Retrovirology, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD 20850, USA.
J Infect Dis. 1996 Feb;173(2):340-8. doi: 10.1093/infdis/173.2.340.
Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro. Prototype strains are adapted to grow in continuous (neoplastic) cell lines and are more susceptible to neutralization than are primary isolates cultured in human peripheral blood mononuclear cells. In this study, 50 sera from nine phase I vaccine trials and 16 from HIV-1-infected persons were evaluated for neutralizing antibody activity against 3 laboratory-adapted and 5 primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the prototype strains; however, none displayed neutralizing activity against primary isolates of HIV-1. Serum from most HIV-1-infected persons neutralized both laboratory-adapted and primary HIV-1 isolates. These data demonstrate a qualitative, or large quantitative, difference in the neutralizing antibody response induced by envelope subunit vaccination and natural HIV-1 infection.
对未感染1型人类免疫缺陷病毒（HIV-1）的志愿者进行的I期研究表明，用包膜亚单位疫苗产品进行免疫接种可引发抗体，这些抗体在体外可中和实验室适应的（原型）HIV-1毒株。原型毒株适应在连续（肿瘤）细胞系中生长，比在人外周血单核细胞中培养的原代分离株更容易被中和。在本研究中，对来自9项I期疫苗试验的50份血清和16份来自HIV-1感染者的血清进行了评估，以检测其对3种实验室适应的和5种原代HIV-1分离株的中和抗体活性。在50份血清中，49份至少中和了1种原型毒株；然而，没有一份对HIV-1原代分离株显示出中和活性。大多数HIV-1感染者的血清可中和实验室适应的和原代HIV-1分离株。这些数据表明，包膜亚单位疫苗接种和自然HIV-1感染诱导的中和抗体反应在质量或数量上存在很大差异。
